Results 221 to 230 of about 7,424,540 (294)

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi, Eric Ricardo Yonatan, Tasia Esterita   +2 more
wiley   +1 more source

Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations-A Case Series. [PDF]

Case Rep Urol
Tessa Djambong R, Follah Feudjio BL, Rysselinck S, Seront E, Niegisch G, Neppl C, Müller A.   +6 more
europepmc   +1 more source

Introduction of a Double‐Headed Nucleotide Into G‐Quadruplex DNA: Position‐Dependent Stabilization and Structural Insights

Chemistry – A European Journal, EarlyView.
A double‐headed bis‐guanine (G) nucleotide (GG) was evaluated as a noncanonical building block in G‐quadruplexes (G4s). Biophysical and computational analyses reveal that GG can directly participate in G‐tetrads and strongly stabilize G4s in a position‐ and topology‐dependent manner. These findings establish design rules for using GG to engineer highly
Krista Urup, Peter Reinholdt, Kasper Munch Beck, Michael Petersen, Jean‐Louis Mergny, Poul Nielsen   +5 more
wiley   +1 more source

1H MR-based detection of human plasma metabolic alterations in clear cell renal cell carcinoma. [PDF]

BJUI Compass
Sharma RK, Solaiyappan M, Feinaj A, Brönimann S, Singla N, Bhujwalla ZM, Ged Y.   +6 more
europepmc   +1 more source

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

Heterogeneous Expression of TREM2 And STAB1 Among Tumor-Associated Macrophages in Clear-Cell Renal Cell Carcinoma. [PDF]

Acta Histochem Cytochem
Shirotani R, Takahashi T, Su J, Uekawa A, Ozaki Y, Ibe Y, Pan C, Yoshii D, Fujiwara Y, Anami T, Nishizawa H, Kurahashi R, Murakami Y, Yatsuda J, Kamba T, Komohara Y.   +15 more
europepmc   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama, Helen Kastrissios, Hossam Kadry, Daping Zhang, Salaheldin Hamed, Srinivasu Poondru, Souvik Bhattacharya, Russ Wada, Amit Garg, Yen Lin Chia   +9 more
wiley   +1 more source

Pembrolizumab and Denosumab in clear-cell renal-cell carcinoma

Clinical Genitourinary Cancer
Carole A. Harris, Danka S. Zebic, Michelle F. Morris, Tom Ferguson, Jeffrey C. Goh, Andrew J. Martin, Craig Underhill, David W. Pook, Laurence Krieger, Ganessan Kichenadasse, Abhishek J. Joshi, Shalini Subramaniam, Alison Zhang, Anthony M. Joshua, Guy C. Toner, Paul A. Vasey, Prashanth Prithviraj, Martin R. Stockler, Ian D. Davis, Craig Gedye   +19 more
openaire   +2 more sources

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source